ArticleProgress in transplantation (Aliso Viejo, Calif.)2019
A National Survey of Transplant Surgeons and Nephrologists on Implementing
Article in Progress in transplantation (Aliso Viejo, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Attitudes and beliefs regarding race-targeted genetic testing of Black people: A systematic review.Journal of genetic counseling · 2023Pooled it
- Apolipoprotein L1 Genetic Testing and Counseling Does Not Reduce Living Kidney Donors' Willingness to Donate : A Hybrid Type 2 Nonrandomized Controlled Trial.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Insights From Black Living Kidney Donors: An Interview Study on APOL1 Genetic Testing Experiences.Clinical transplantation · 2026Observational
- Non-HLA Genetics and Application to Living Donor Candidates.Current transplantation reports · 2025Article
- Development and Evaluation of a Culturally TargetedKidney medicine · 2025Article
- Contextual factors of implementing APOL1 genetic testing into living kidney donor clinical evaluation.Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Article
- Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study.Clinical transplantation · 2024Article
- Nephrologists' Views on a Workflow for Returning Genetic Results to Research Participants.Kidney international reports · 2024Article
- Development of a culturally targeted chatbot to inform living kidney donor candidates of African ancestry about APOL1 genetic testing: a mixed methods study.Journal of community genetics · 2024Article
- A Conceptual Model to Achieve Health Equity in APOL-1 Clinical Studies.Health equity · 2024Article
- The ties that transplant: The social capital determinants of the living kidney donor relationship distribution.Social science research · 2023Article
- Implementation of a culturally competentBMJ open · 2023Article
- Gender and race/ethnicity differences in living kidney donor demographics: Preference or disparity?Transplantation reviews (Orlando, Fla.) · 2021Review
- Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Mainstreaming Genetic Testing for Adult Patients With Autosomal Dominant Polycystic Kidney Disease.Canadian journal of kidney health and disease · 2021Article
- Apolipoprotein L1: role in the evaluation of kidney transplant donors.Current opinion in nephrology and hypertension · 2020Article
- Variation ofProgress in transplantation (Aliso Viejo, Calif.) · 2020Article
- Incorporating apolipoprotein L1 testing into evaluation of potential living kidney donors: a single-centre experience.Clinical kidney journal · 2019Article
- African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThere is debate over whether Apolipoprotein L1 (APOL1) gene risk variants contribute to African American (AA) live donors' (LD) increased risk of kidney failure. Little is known about factors influencing physicians' integration of APOL1 genetic testing of AA LDs into donor evaluation.
designWe conducted a cross-sectional survey, informed by Roger's Diffusion of Innovations theory, among nephrology and surgeon members of the American Society of Nephrology, American Society of Transplantation, and American Society of Transplant Surgeons about their practices of and attitudes about APOL1 genetic testing of AA potential LDs. Descriptive statistics and bivariate analyses were performed.
resultsOf 383 completed surveys, most physicians believed that APOL1 testing can help AA LDs make more informed donation decisions (87%), and the addition of APOL1 testing offers better clinical information about AA LD's eligibility for donation than existing evaluation approaches (74%). Among respondents who evaluate LDs (n = 345), 63% would definitely or probably begin or continue using APOL1 testing in the next year, however, few use APOL1 testing routinely (4%) or on a case-by-case basis (14%). Most did not know the right clinical scenario to order APOL1 testing (59%), but would use educational materials to counsel AA LDs about APOL1 testing (97%). DISCUSSION: Although physicians were highly supportive of APOL1 genetic testing for AA LDs, few physicians use APOL1 testing. As more physicians intend to use APOL1 testing, an ethical framework and clinical decision support are needed presently to assist clinicians in clarifying the proper indication of APOL1 genetic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.